Rezpegaldesleukin
Rezpegaldesleukin is a regulatory-T-cell-selective IL-2 conjugate designed to restore immune balance. Nektar has evaluated it in autoimmune diseases including alopecia areata (the REZOLVE-AA study) and atopic dermatitis.
Also known as: REZPEG, NKTR-358, LY3471851
Rezpegaldesleukin forecasting benchmarks
1 benchmarkMechanism & molecular targets
Indications studied
Developed by
About Rezpegaldesleukin
What is Rezpegaldesleukin?
Rezpegaldesleukin is a regulatory-T-cell-selective IL-2 conjugate designed to restore immune balance. Nektar has evaluated it in autoimmune diseases including alopecia areata (the REZOLVE-AA study) and atopic dermatitis. It is a treg-selective il-2 conjugate developed by Nektar Therapeutics.
What does Rezpegaldesleukin target?
Rezpegaldesleukin acts on Regulatory T cells (IL-2 / Treg axis).
How well do AI models predict Rezpegaldesleukin trial outcomes?
Open any benchmark below to see the full model leaderboard scored by accuracy, Brier score, and log loss. Models forecast each readout before it is public, so the scores reflect genuine predictive skill rather than hindsight.